Hema e‐Chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. (22nd December 2012)

• Record Type: Journal Article
• Authors: Nosari, A. M.; Caira, M.; Pioltelli, M. L.; Fanci, R.; Bonini, A.; Cattaneo, C.; Castagnola, C.; Capalbo, S. F.; De Fabritiis, P.; Mettivier, V.; Morselli, M.; Pastore, D.; Aversa, F.; Rossi, G.; Pagano, L.
• Is Part Of: Clinical microbiology and infection. Volume 19:Number 8(2013:Aug.)
• Page Start: 757
• Page End: 762
• Publication Date: 2012-12-22
• Subjects: Attributable mortality -- galactomannan antigen -- haematological malignancies -- mould infections -- yeast infections; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1111/1469-0691.12014
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract : Clin Microbiol Infect Abstract: The electronic surveillance system Hema e‐Chart allowed us to prospectively collect data and to perform an analysis of invasive fungal infections (IFI) diagnosed in febrile patients as well as the procedures allowing their diagnosis and outcome according to the treatment given. Every patient admitted to 26 Italian Haematology Units with a new diagnosis of haematological malignancy and who was a candidate for chemotherapy was consecutively registered between March 2007 and March 2009. In all, 147 haematological patients with mycoses were identified. Yeasts were found in 23 infections; moulds were diagnosed in 17 proven, 35 probable and 72 possible mycoses. Galactomannan (GM) antigen was the most important test to diagnose probable mould infection; it was positive (cut‐off >0.5) in 27 (77%) probable and in nine (53%) proven mould infections. Among patients with probable/proven mould infection who received no prophylaxis or non‐mould‐active prophylaxis with fluconazole, more patients ( n = 26, 78.8%) had GM antigen positivity compared with patients ( n = 10, 52.6%) given prophylaxis with mould‐active drugs (p <0.05). First‐line antifungal therapy was effective in 11/23 (48%) yeast infections and in 37/52 (71.2%) proven/probable mould infections. Twenty patients (14%) died within 12 weeks. The fungal attributable mortality was 30.4% and 17.3% in yeast and proven/probable mould infections, respectively. Among risk factors only age was independently associated (p 0.013) with mortality; sex, underlying haematological malignancy, previous prophylaxis and presence of neutropenia at diagnosis were not significant. A diagnosis of mould infection seemed to have a trend for a better outcome than the diagnosis of yeast infection (p 0.064).